UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

The Lancet (British edition), 2009-09, Vol.374 (9692), p.796-806

2009

Volltextzugriff (PDF)

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

The Lancet infectious diseases, 2013-07, Vol.13 (7), p.587-596

2013

Volltextzugriff (PDF)

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study

Hepatology (Baltimore, Md.), 2012-09, Vol.56 (3), p.884-893

2012

Volltextzugriff (PDF)

Monosynaptic Restriction of Transsynaptic Tracing from Single, Genetically Targeted Neurons

Neuron (Cambridge, Mass.), 2007-03, Vol.53 (5), p.639-647

2007

Volltextzugriff (PDF)

Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity

Journal of medicinal chemistry, 2021-04, Vol.64 (8), p.4709-4729

2021

Volltextzugriff (PDF)

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2‑Substituted Benzamide Zinc Binding Group

ACS medicinal chemistry letters, 2020-12, Vol.11 (12), p.2476-2483

2020

Volltextzugriff (PDF)

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence

Proceedings of the National Academy of Sciences - PNAS, 2018-07, Vol.115 (30), p.E7139-E7148

2018

Volltextzugriff (PDF)

Imaging Individual Retroviral Fusion Events: From Hemifusion to Pore Formation and Growth

Proceedings of the National Academy of Sciences - PNAS, 2005-06, Vol.102 (24), p.8728-8733

2005

Volltextzugriff (PDF)

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV‑1 Protein for Clearance

ACS medicinal chemistry letters, 2020-07, Vol.11 (7), p.1476-1483

2020

Volltextzugriff (PDF)

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Clinical infectious diseases, 2014-12, Vol.59 (12), p.1657-1665

2014

Volltextzugriff (PDF)

Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel In Vitro Pharmacodynamic System

Antimicrobial Agents and Chemotherapy, 2012-03, Vol.56 (3), p.1170-1181

2012

Volltextzugriff (PDF)

Low pH Is Required for Avian Sarcoma and Leukosis Virus Env-Dependent Viral Penetration into the Cytosol and Not for Viral Uncoating

Journal of Virology, 2004-10, Vol.78 (19), p.10433-10441

2004

Volltextzugriff (PDF)

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

Journal of acquired immune deficiency syndromes (1999), 2010-09, Vol.55 (1), p.39

2010

Volltextzugriff (PDF)

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation

Bioorganic & medicinal chemistry letters, 2020-07, Vol.30 (13), p.127197-127197, Article 127197

2020

Volltextzugriff (PDF)

Two Retroviral Entry Pathways Distinguished by Lipid Raft Association of the Viral Receptor and Differences in Viral Infectivity

Journal of Virology, 2003-02, Vol.77 (3), p.1977-1983

2003

Volltextzugriff (PDF)

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals

EBioMedicine, 2015-08, Vol.2 (8), p.874-883

2015

Volltextzugriff (PDF)

Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir

Bioorganic & medicinal chemistry letters, 2020-09, Vol.30 (17), p.127367-127367, Article 127367

2020

Volltextzugriff (PDF)

Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation

Bioorganic & medicinal chemistry letters, 2021-09, Vol.47, p.128168-128168, Article 128168

2021

Volltextzugriff (PDF)

SNARE-Complex Disassembly by NSF Follows Synaptic-Vesicle Fusion

Proceedings of the National Academy of Sciences - PNAS, 2001-10, Vol.98 (21), p.12233-12238

2001

Volltextzugriff (PDF)

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat

Journal of virology, 2020-06, Vol.94 (13)

2020

Volltextzugriff (PDF)

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

Virology (New York, N.Y.), 2013-09, Vol.444 (1), p.329-336

2013

Volltextzugriff (PDF)

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3

Journal of hepatology, 2013-07, Vol.59 (1), p.31-37

2013

Volltextzugriff (PDF)

Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction

ACS medicinal chemistry letters, 2021-04, Vol.12 (4), p.540-547

2021

Volltextzugriff (PDF)

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis

Clinical gastroenterology and hepatology, 2014-06, Vol.12 (6), p.1029-1037.e5

2014

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(35)
Humans
(28)
Female
(12)
Male
(12)
Adult
(11)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Infectious Diseases
(10)
Middle Aged
(10)
Pharmacology & Pharmacy
(10)
Treatment Outcome
(9)
Virology
(9)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(8)
Antiviral Agents
(8)
Chemistry, Medicinal
(8)
Hiv
(8)
Hiv Infections - Drug Therapy
(8)
Human Viral Diseases
(8)
Pharmacology. Drug Treatments
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: A randomized phase II study

Monosynaptic Restriction of Transsynaptic Tracing from Single, Genetically Targeted Neurons

Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity

Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2‑Substituted Benzamide Zinc Binding Group

Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence

Imaging Individual Retroviral Fusion Events: From Hemifusion to Pore Formation and Growth

Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV‑1 Protein for Clearance

Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection

Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a Novel In Vitro Pharmacodynamic System

Low pH Is Required for Avian Sarcoma and Leukosis Virus Env-Dependent Viral Penetration into the Cytosol and Not for Viral Uncoating

Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses

Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation

Two Retroviral Entry Pathways Distinguished by Lipid Raft Association of the Viral Receptor and Differences in Viral Infectivity

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals

Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir

Discovery of macrocyclic HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation

SNARE-Complex Disassembly by NSF Follows Synaptic-Vesicle Fusion

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat

Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3

Redefining the Histone Deacetylase Inhibitor Pharmacophore: High Potency with No Zinc Cofactor Interaction

Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis

Suchergebnisse filtern